Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017
October 18 2017 - 4:05PM
Business Wire
– Conference Call and Webcast to Follow at 5:00
p.m. EDT/ 2:00 p.m. PDT –
Exelixis, Inc. (NASDAQ:EXEL) announced today that its third
quarter 2017 financial results will be released on Wednesday,
November 1, 2017 after the markets close. At 5:00 p.m. EDT / 2:00
p.m. PDT, Exelixis management will host a conference call to
discuss the results and provide a general business update. The
conference call will be accessible via the Internet from the
company’s website.
To access the webcast link, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
listen to the webcast. Alternatively, please call (855) 793-2457
(domestic) or (631) 485-4921 (international) and provide the
conference call passcode 96645455 to join by phone.
A telephone replay will be available until 8:00 p.m. EDT on
November 3, 2017. Access numbers for the telephone replay are:
855-859-2056 (domestic) and 404-537-3406 (international); the
passcode is 96645455. A webcast replay will also be archived on
www.exelixis.com for one year.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our lead compounds, cabozantinib and
cobimetinib, and advanced them into clinical development before
entering into partnerships with leading biopharmaceutical companies
in our efforts to bring them to patients globally. With growing
revenues from the three resulting commercialized products –
CABOMETYX®, COMETRIQ®, and COTELLIC® – we are reinvesting in our
business to maximize the potential of our pipeline, which we intend
to supplement with targeted business development activities and
internal drug discovery, all to deliver the next generation of
Exelixis medicines and help patients recover stronger and live
longer. For more information about Exelixis, please visit
www.exelixis.com or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171018006466/en/
Exelixis, Inc.Susan Hubbard, 650-837-8194Executive Vice
President, Public Affairs & Investor
Relationsshubbard@exelixis.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024